About Mucosal addressin cell adhesion molecule 1
Mucosal addressin cell adhesion molecule 1 (MADCAM1) is a protein
from Homo sapiens identified by UniProt accession
Q13477, 382 residues long.
MolForge cross-references it against 0 known binders and
218 disease associations.
Target properties
| Protein name | Mucosal addressin cell adhesion molecule 1 |
| UniProt accession | Q13477 |
| Gene | MADCAM1 |
| Organism | Homo sapiens |
| Length | 382 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (218)
Diseases linked to this target (Open Targets).
- ulcerative colitis · score 0.38
- Crohn's disease · score 0.38
- type 1 diabetes mellitus · score 0.23
- experimental autoimmune encephalomyelitis · score 0.08
- hepatocellular carcinoma · score 0.07
- common variable immunodeficiency · score 0.06
- isolated agammaglobulinemia · score 0.06
- BENTA disease · score 0.06
- combined immunodeficiency with skin granulomas · score 0.05
- hyper-IgM syndrome type 3 · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q13477-F1 | alphafold | PREDICTED | 74.63 | — |
Amino-acid sequence (382 residues)
MDFGLALLLA GLLGLLLGQS LQVKPLQVEP PEPVVAVALG ASRQLTCRLA CADRGASVQW RGLDTSLGAV QSDTGRSVLT VRNASLSAAG TRVCVGSCGG RTFQHTVQLL VYAFPDQLTV SPAALVPGDP EVACTAHKVT PVDPNALSFS LLVGGQELEG AQALGPEVQE EEEEPQGDED VLFRVTERWR LPPLGTPVPP ALYCQATMRL PGLELSHRQA IPVLHSPTSP EPPDTTSPES PDTTSPESPD TTSQEPPDTT SPEPPDKTSP EPAPQQGSTH TPRSPGSTRT RRPEISQAGP TQGEVIPTGS SKPAGDQLPA ALWTSSAVLG LLLLALPTYH LWKRCRHLAE DDTHPPASLR LLPQVSAWAG LRGTGQVGIS PS
Explore Mucosal addressin cell adhesion molecule 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets